Preclinical evaluation of miR-15/107 family members as multifactorial drug targets for Alzheimer's disease

Molecular Therapy Nucleic Acids

Volumn 4, Issue , 2015, Pages e256-

  Parsi, Sepideh ^a,b   Smith, Pascal Y ^a,b   Goupil, Claudia ^a,b   Dorval, Véronique ^a,b   Hébert, Sébastien S ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Alzheimer's disease; brain delivery; microRNA; miR 16; therapy

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; CD71 ANTIGEN; MICRORNA; MICRORNA 107; MICRORNA 15; MICRORNA 16; MITOGEN ACTIVATED PROTEIN KINASE 3; NICASTRIN; PROTEIN BCL 2; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN STEM; CORPUS STRIATUM; DRUG TARGETING; FEMALE; HEK293 CELL LINE; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MIMICRY; MOUSE; NERVE CELL; NERVE DEGENERATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS;

EID: 84943427950     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.33     Document Type: Article

References (92)

1. Prince, M, Bryce, R, Albanese, E, Wimo, A, Ribeiro, W, and Ferri, CP. (2013). The global prevalence of dementia: a systematic review, and metaanalysis. Alzheimers Dement 9: 63-75.e2
2. Campion, D, Dumanchin, C, Hannequin, D, Dubois, B, Belliard, S, Puel, M, et al. (1999). Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 65: 664-670
3. Sperling, RA, Aisen, PS, Beckett, LA, Bennett, DA, Craft, S, Fagan, AM, et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for alzheimer's disease. Alzheimers Dement 7: 280-292
4. De Strooper, B, Iwatsubo, T, and Wolfe, MS. (2012). Presenilins, and γ-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb Perspect Med 2: a006304
5. Hardy, J, and Selkoe, DJ. (2002). The amyloid hypothesis of Alzheimer's disease: progress, and problems on the road to therapeutics. Science 297: 353-356
6. Jia, Q, Deng, Y, and Qing, H. (2014). Potential therapeutic strategies for alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials. Biomed Res Int 2014: 837157
7. Boutajangout, A, and Wisniewski, T. (2014). Tau-based therapeutic approaches for alzheimer's disease - a mini-review. Gerontology 60: 381-385
8. Rosenblum, WI. (2014). Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. Neurobiol Aging 35: 969-974
9. Jaturapatporn, D, Isaac, MG, McCleery, J, and Tabet, N. (2012). Aspirin, steroidal, and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2: CD006378
10. Carreiras, MC, Mendes, E, Perry, MJ, Francisco, AP, and Marco-Contelles, J. (2013). The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr Top Med Chem 13: 1745-1770
11. Hébert, SS, Wang, WX, Zhu, Q, and Nelson, PT. (2013). A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer's disease, dementia with lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. J Alzheimers Dis 35: 335-348
12. Ambros, V. (2004). The functions of animal microRNAs. Nature 431: 350-355
13. He, L, and Hannon, GJ. (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531
14. Bartel, DP. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297
15. van Rooij, E, and Kauppinen, S. (2014). Development of microRNA therapeutics is coming of age. EMBO Mol Med 6: 851-864
16. Ling, H, Fabbri, M, and Calin, GA. (2013). MicroRNAs, and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12: 847-865
17. Jackson, AL, and Levin, AA. (2012). Developing microRNA therapeutics: approaching the unique complexities. Nucleic Acid Ther 22: 213-225
18. Hammond, SM. (2007). MicroRNAs as tumor suppressors. Nat Genet 39: 582-583
19. Bader, AG, Brown, D, and Winkler, M. (2010). The promise of microRNA replacement therapy. Cancer Res 70: 7027-7030
20. Simonson, B, and Das, S. (2015). MicroRNA Therapeutics: the Next Magic Bullet?. Mini Rev Med Chem 15: 467-474
21. Bader, AG. (2012). miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 3: 120
22. Pasquinelli, AE. (2012). MicroRNAs, and their targets: recognition, regulation, and an emerging reciprocal relationship. Nat Rev Genet 13: 271-282
23. Finnerty, JR, Wang, WX, Hébert, SS, Wilfred, BR, Mao, G, and Nelson, PT. (2010). The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol 402: 491-509
24. Linsley, PS, Schelter, J, Burchard, J, Kibukawa, M, Martin, MM, Bartz, SR, et al. (2007). Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol 27: 2240-2252
25. Müller, M, Kuiperij, HB, Claassen, JA, Küsters, B, and Verbeek, MM. (2014). MicroRNAs in Alzheimer's disease: differential expression in hippocampus, and cell-free cerebrospinal fluid. Neurobiol Aging 35: 152-158
26. Liu, W, Liu, C, Zhu, J, Shu, P, Yin, B, Gong, Y, et al. (2012). MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice. Neurobiol Aging 33: 522-534
27. Wang, WX, Huang, Q, Hu, Y, Stromberg, AJ, and Nelson, PT. (2011). Patterns of microRNA expression in normal, and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta Neuropathol 121: 193-205
28. Hébert, SS, Horré, K, Nicolaï, L, Papadopoulou, AS, Mandemakers, W, Silahtaroglu, AN, et al. (2008). Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA 105: 6415-6420
29. Shioya, M, Obayashi, S, Tabunoki, H, Arima, K, Saito, Y, Ishida, T, et al. (2010). Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol Appl Neurobiol 36: 320-330
30. Nunez-Iglesias, J, Liu, CC, Morgan, TE, Finch, CE, and Zhou, XJ. (2010). Joint genomewide profiling of miRNA, and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation. PLoS One 5: e8898
31. Hébert, SS, Papadopoulou, AS, Smith, P, Galas, MC, Planel, E, Silahtaroglu, AN, et al. (2010). Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation, and neurodegeneration. Hum Mol Genet 19: 3959-3969
32. Cogswell, JP, Ward, J, Taylor, IA, Waters, M, Shi, Y, Cannon, B, et al. (2008). Identification of miRNA changes in Alzheimer's disease brain, and CSF yields putative biomarkers, and insights into disease pathways. J Alzheimers Dis 14: 27-41
33. Ai, J, Sun, LH, Che, H, Zhang, R, Zhang, TZ, Wu, WC, et al. (2013). MicroRNA-195 protects against dementia induced by chronic brain hypoperfusion via its antiamyloidogenic effect in rats. J Neurosci 33: 3989-4001
34. Wang, WX, Rajeev, BW, Stromberg, AJ, Ren, N, Tang, G, Huang, Q, et al. (2008). The expression of microRNA miR-107 decreases early in Alzheimer's disease, and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 28: 1213-1223
35. Nelson, PT, and Wang, WX. (2010). MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study. J Alzheimers Dis 21: 75-79
36. Smith, P, Al Hashimi, A, Girard, J, Delay, C, and Hébert, SS. (2011). In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs. J Neurochem 116: 240-247
37. Zhu, HC, Wang, LM, Wang, M, Song, B, Tan, S, Teng, JF, et al. (2012). MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1. Brain Res Bull 88: 596-601
38. van Rooij, E, Purcell, AL, and Levin, AA. (2012). Developing microRNA therapeutics. Circ Res 110: 496-507
39. Jopling, CL. (2010). Targeting microRNA-122 to Treat Hepatitis C Virus Infection. Viruses 2: 1382-1393
40. Patel, N, Hoang, D, Miller, N, Ansaloni, S, Huang, Q, Rogers, JT, et al. (2008). MicroRNAs can regulate human APP levels. Mol Neurodegener 3: 10
41. Absalon, S, Kochanek, DM, Raghavan, V, and Krichevsky, AM. (2013). MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci 33: 14645-14659
42. Ancolio, K, Dumanchin, C, Barelli, H, Warter, JM, Brice, A, Campion, D, et al. (1999). Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 -> Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease. Proc Natl Acad Sci USA 96: 4119-4124
43. Planel, E, Krishnamurthy, P, Miyasaka, T, Liu, L, Herman, M, Kumar, A, et al. (2008). Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo. J Neurosci 28: 12798-12807
44. Calin, GA, Dumitru, CD, Shimizu, M, Bichi, R, Zupo, S, Noch, E, et al. (2002). Frequent deletions, and down-regulation of micro- RNA genes miR15, and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529
45. Koval, ED, Shaner, C, Zhang, P, du Maine, X, Fischer, K, Tay, J, et al. (2013). Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum Mol Genet 22: 4127-4135
46. Wilkes, D. (2014). Programmable intrathecal pumps for the management of chronic pain: recommendations for improved efficiency. J Pain Res 7: 571-577
47. Grondin, R, Ge, P, Chen, Q, Sutherland, JE, Zhang, Z, Gash, DM, et al. (2015). Onset Time, and Durability of Huntingtin Suppression in Rhesus Putamen After Direct Infusion of Antihuntingtin siRNA. Mol Ther Nucleic Acids 4: e245
48. Wesemann, K, Coffey, RJ, Wallace, MS, Tan, Y, Broste, S, and Buvanendran, A. (2014). Clinical accuracy, and safety using the SynchroMed II intrathecal drug infusion pump. Reg Anesth Pain Med 39: 341-346
49. Dweep, H, Sticht, C, Pandey, P, and Gretz, N. (2011). miRWalk-database: prediction of possible miRNA binding sites by walking the genes of three genomes. J Biomed Inform 44: 839-847
50. Delay, C, Dorval, V, Fok, A, Grenier-Boley, B, Lambert, JC, Hsiung, GY, et al. (2014). MicroRNAs targeting Nicastrin regulate Aβ production, and are affected by target site polymorphisms. Front Mol Neurosci 7: 67
51. Zhou, R, Li, X, Hu, G, Gong, AY, Drescher, KM, and Chen, XM. (2012). miR-16 targets transcriptional corepressor SMRT, and modulates NF-kappaB-regulated transactivation of interleukin-8 gene. PLoS One 7: e30772
52. Frasca, D, Diaz, A, Romero, M, Ferracci, F, and Blomberg, BB. (2015). MicroRNAs miR-155, and miR-16 Decrease AID, and E47 in B Cells from Elderly Individuals. J Immunol 195: 2134-2140
53. Padurariu, M, Ciobica, A, Mavroudis, I, Fotiou, D, and Baloyannis, S. (2012). Hippocampal neuronal loss in the CA1, and CA3 areas of Alzheimer's disease patients. Psychiatr Danub 24: 152-158
54. Grinberg, LT, Rueb, U, and Heinsen, H. (2011). Brainstem: neglected locus in neurodegenerative diseases. Front Neurol 2: 42
55. Simic, G, Stanic, G, Mladinov, M, Jovanov-Milosevic, N, Kostovic, I, and Hof, PR. (2009). Does Alzheimer's disease begin in the brainstem?. Neuropathol Appl Neurobiol 35: 532-554
56. Wiese, S, Reidegeld, KA, Meyer, HE, and Warscheid, B. (2007). Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research. Proteomics 7: 340-350
57. Warde-Farley, D, Donaldson, SL, Comes, O, Zuberi, K, Badrawi, R, Chao, P, et al. (2010). The GeneMANIA prediction server: biological network integration for gene prioritization, and predicting gene function. Nucleic Acids Res 38(Web Server issue): W214-W220
58. Huang, da W, Sherman, BT, and Lempicki, RA. (2009). Systematic, and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57
59. Wang, WX, Wilfred, BR, Madathil, SK, Tang, G, Hu, Y, Dimayuga, J, et al. (2010). miR-107 regulates granulin/progranulin with implications for traumatic brain injury, and neurodegenerative disease. Am J Pathol 177: 334-345
60. Ren, Y, Hauert, S, Lo, JH, and Bhatia, SN. (2012). Identification, and characterization of receptor-specific peptides for siRNA delivery. ACS Nano 6: 8620-8631
61. Trang, P, Wiggins, JF, Daige, CL, Cho, C, Omotola, M, Brown, D, et al. (2011). Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19: 1116-1122
62. Di Martino, MT, Campani, V, Misso, G, Gallo Cantafio, ME, Gullà, A, Foresta, U, et al. (2014). In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS One 9: e90005
63. Thomson, DW, Bracken, CP, Szubert, JM, and Goodall, GJ. (2013). On measuring miRNAs after transient transfection of mimics or antisense inhibitors. PLoS One 8: e55214
64. Zhang, Y, Wang, Z, and Gemeinhart, RA. (2013). Progress in microRNA delivery. J Control Release 172: 962-974
65. Robakis, NK. (2014). Cell signaling abnormalities may drive neurodegeneration in familial Alzheimer disease. Neurochem Res 39: 570-575
66. Magen, I, and Hornstein, E. (2014). Oligonucleotide-based therapy for neurodegenerative diseases. Brain Res 1584: 116-128
67. Hanbury, R, Ling, ZD, Wuu, J, and Kordower, JH. (2003). GFAP knockout mice have increased levels of GDNF that protect striatal neurons from metabolic, and excitotoxic insults. J Comp Neurol 461: 307-316
68. Furman, JL, Sama, DM, Gant, JC, Beckett, TL, Murphy, MP, Bachstetter, AD, et al. (2012). Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci 32: 16129-16140
69. Hol, EM, Roelofs, RF, Moraal, E, Sonnemans, MA, Sluijs, JA, Proper, EA, et al. (2003). Neuronal expression of GFAP in patients with Alzheimer pathology, and identification of novel GFAP splice forms. Mol Psychiatry 8: 786-796
70. Meraz-Ríos, MA, Toral-Rios, D, Franco-Bocanegra, D, Villeda-Hernández, J, and Campos-Peña, V. (2013). Inflammatory process in Alzheimer's Disease. Front Integr Neurosci 7: 59
71. An, F, Gong, B, Wang, H, Yu, D, Zhao, G, Lin, L, et al. (2012). miR-15b, and miR-16 regulate TNF mediated hepatocyte apoptosis via BCL2 in acute liver failure. Apoptosis 17: 702-716
72. Spillantini, MG, Schmidt, ML, Lee, VM, Trojanowski, JQ, Jakes, R, and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature 388: 839-840
73. Nonaka, T, Watanabe, ST, Iwatsubo, T, and Hasegawa, M. (2010). Seeded aggregation, and toxicity of {alpha}-synuclein, and tau: cellular models of neurodegenerative diseases. J Biol Chem 285: 34885-34898
74. Raven, EP, Lu, PH, Tishler, TA, Heydari, P, and Bartzokis, G. (2013). Increased iron levels, and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging. J Alzheimers Dis 37: 127-136
75. Huang, XT, Qian, ZM, He, X, Gong, Q, Wu, KC, Jiang, LR, et al. (2014). Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer's disease. Neurobiol Aging 35: 1045-1054
76. Hunker, CM, Galvis, A, Kruk, I, Giambini, H, Veisaga, ML, and Barbieri, MA. (2006). Rab5-activating protein 6, a novel endosomal protein with a role in endocytosis. Biochem Biophys Res Commun 340: 967-975
77. Leto, D, and Saltiel, AR. (2012). Regulation of glucose transport by insulin: traffic control of GLUT4. Nat Rev Mol Cell Biol 13: 383-396
78. Blencowe, BJ, Issner, R, Nickerson, JA, and Sharp, PA. (1998). A coactivator of pre-mRNA splicing. Genes Dev 12: 996-1009
79. Shehadeh, LA, Yu, K, Wang, L, Guevara, A, Singer, C, Vance, J, et al. (2010). SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease. PLoS One 5: e9104
80. Blair, LJ, Nordhues, BA, Hill, SE, Scaglione, KM, O'Leary, JC 3rd, Fontaine, SN, et al. (2013). Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest 123: 4158-4169
81. Liang, WS, Dunckley, T, Beach, TG, Grover, A, Mastroeni, D, Walker, DG, et al. (2007). Gene expression profiles in anatomically, and functionally distinct regions of the normal aged human brain. Physiol Genomics 28: 311-322
82. Baskerville, KA, Kent, C, Personett, D, Lai, WR, Park, PJ, Coleman, P, et al. (2008). Aging elevates metabolic gene expression in brain cholinergic neurons. Neurobiol Aging 29: 1874-1893
83. Junn, E, and Mouradian, MM. (2012). MicroRNAs in neurodegenerative diseases, and their therapeutic potential. Pharmacol Ther 133: 142-150
84. Park, CY, Choi, YS, and McManus, MT. (2010). Analysis of microRNA knockouts in mice. Hum Mol Genet 19(R2): R169-R175
85. Vidigal, JA, and Ventura, A. (2015). The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol 25: 137-147
86. Aqeilan, RI, Calin, GA, and Croce, CM. (2010). miR-15a, and miR-16-1 in cancer: discovery, function, and future perspectives. Cell Death Differ 17: 215-220
87. Yang, TQ, Lu, XJ, Wu, TF, Ding, DD, Zhao, ZH, Chen, GL, et al. (2014). MicroRNA-16 inhibits glioma cell growth, and invasion through suppression of BCL2, and the nuclear factor-κB1/MMP9 signaling pathway. Cancer Sci 105: 265-271
88. Chen, L, Wang, Q, Wang, GD, Wang, HS, Huang, Y, Liu, XM, et al. (2013). miR-16 inhibits cell proliferation by targeting IGF1R, and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma. FEBS Lett 587: 1366-1372
89. Calin, GA, Cimmino, A, Fabbri, M, Ferracin, M, Wojcik, SE, Shimizu, M, et al. (2008). MiR-15a, and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 105: 5166-5171
90. Hébert, SS, Horré, K, Nicolaï, L, Bergmans, B, Papadopoulou, AS, Delacourte, A, et al. (2009). MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. Neurobiol Dis 33: 422-428
91. Dorval, V, Mandemakers, W, Jolivette, F, Coudert, L, Mazroui, R, De Strooper, B, et al. (2014). Gene, and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models. PLoS One 9: e85510
92. Wang, WX, Wilfred, BR, Hu, Y, Stromberg, AJ, and Nelson, PT. (2010). Anti-Argonaute RIP-Chip shows that miRNA transfections alter global patterns of mRNA recruitment to microribonucleoprotein complexes. RNA 16: 394-404